These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 31468315)
41. Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD. Fabbri LM; Kerwin EM; Spangenthal S; Ferguson GT; Rodriguez-Roisin R; Pearle J; Sethi S; Orevillo C; Darken P; St Rose E; Fischer T; Golden M; Dwivedi S; Reisner C Respir Res; 2016 Sep; 17(1):109. PubMed ID: 27586537 [TBL] [Abstract][Full Text] [Related]
42. Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naïve patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials. Zheng J; Xu JF; Jenkins M; Assam PN; Wang L; Lipworth BJ Respir Res; 2020 Mar; 21(1):69. PubMed ID: 32164675 [TBL] [Abstract][Full Text] [Related]
43. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease. Carter NJ Drugs; 2013 May; 73(7):741-53. PubMed ID: 23677802 [TBL] [Abstract][Full Text] [Related]
44. Efficacy and Safety of Inhaled Glycopyrronium Bromide in COPD: A Randomized, Parallel Group, Dose-Ranging Study (GLIMMER). Kerwin E; Feldman G; Pearle J; De La Cruz L; Edwards M; Beaudot C; Georges G COPD; 2021 Apr; 18(2):181-190. PubMed ID: 33709856 [TBL] [Abstract][Full Text] [Related]
45. Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD - A randomised, multicentre, crossover trial. Watz H; Mailänder C; May C; Baier M; Kirsten AM Pulm Pharmacol Ther; 2017 Feb; 42():13-20. PubMed ID: 27940287 [TBL] [Abstract][Full Text] [Related]
46. Drug Delivery from an Innovative LAMA/LABA Co-suspension Delivery Technology Fixed-Dose Combination MDI: Evidence of Consistency, Robustness, and Reliability. Doty A; Schroeder J; Vang K; Sommerville M; Taylor M; Flynn B; Lechuga-Ballesteros D; Mack P AAPS PharmSciTech; 2018 Feb; 19(2):837-844. PubMed ID: 29019170 [TBL] [Abstract][Full Text] [Related]
47. Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide. Mantero M; Radovanovic D; Santus P; Blasi F Int J Chron Obstruct Pulmon Dis; 2018; 13():2319-2333. PubMed ID: 30104872 [TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Noonan M; Rosenwasser LJ; Martin P; O'Brien CD; O'Dowd L Drugs; 2006; 66(17):2235-54. PubMed ID: 17137405 [TBL] [Abstract][Full Text] [Related]
49. Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison. Medic G; Lindner L; van der Weijden M; Karabis A Adv Ther; 2016 Mar; 33(3):379-99. PubMed ID: 26883661 [TBL] [Abstract][Full Text] [Related]
50. Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease. Babu KS; Morjaria JB Ther Adv Respir Dis; 2015 Apr; 9(2):56-68. PubMed ID: 25754881 [TBL] [Abstract][Full Text] [Related]
51. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety. Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493 [TBL] [Abstract][Full Text] [Related]
52. Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD. Kerwin EM; Siler TM; Arora S; Darken P; Rose E; Reisner C Int J Chron Obstruct Pulmon Dis; 2018; 13():1483-1494. PubMed ID: 29773947 [TBL] [Abstract][Full Text] [Related]
56. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404 [TBL] [Abstract][Full Text] [Related]
57. Consistent Pulmonary Drug Delivery with Whole Lung Deposition Using the Aerosphere Inhaler: A Review of the Evidence. Usmani OS; Roche N; Jenkins M; Stjepanovic N; Mack P; De Backer W Int J Chron Obstruct Pulmon Dis; 2021; 16():113-124. PubMed ID: 33500616 [TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial. Rhee CK; Park HY; Park JW; Lee JH; Kim TH; Lee SW; Jung JY; Kim S; Hwang YI; Jung KS Trials; 2017 Feb; 18(1):80. PubMed ID: 28228162 [TBL] [Abstract][Full Text] [Related]
59. GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond. Rabe KF Expert Rev Clin Pharmacol; 2017 Jul; 10(7):685-698. PubMed ID: 28443352 [TBL] [Abstract][Full Text] [Related]
60. Formoterol: a review of its use in chronic obstructive pulmonary disease. Cheer SM; Scott LJ Am J Respir Med; 2002; 1(4):285-300. PubMed ID: 14720051 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]